Menu

Walgreens Sues Theranos for $140 Million

The drugstore giant is accusing the blood-testing company of breach of contract, although the full details of the suit have not been disclosed.

Nov 10, 2016
Joshua A. Krisch

In another blow to Theranos, the Silicon Valley startup that closed its blood-testing labs and fired hundreds of employees in 2015 following federal investigations into its practices, one of the company’s erstwhile partners, Walgreens, has initiated a $140 million lawsuit, The Wall Street Journal reported. The complaint was filed under seal, so details remain scant, but Walgreens confirmed that a suit against Theranos is pending.

The relationship between Walgreens and Theranos began in 2013, with Walgreens agreeing to use Theranos’s blood-testing technology in 40 of its Arizona locations. When the Theranos probe came to light, Walgreens pulled all 40 testing sites from its locations.

Theranos released a statement on November 8 that vigorously denied any wrongdoing, and placed the blame squarely on the drugstore giant. “Over the years, Walgreens consistently failed to meet its commitments to Theranos,” the startup wrote. “Through its mishandling of our partnership and now this lawsuit, Walgreens has caused Theranos and its investors significant harm.” 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.